Alpspitz Bioscience

Executive Summary

Alpspitz Bioscience, founded in 2018 and based in Munich, Germany, is a diagnostics startup developing DefenceDX, a non-invasive, saliva-based health screening platform. The platform leverages artificial intelligence and immunology to detect inflammatory biomarkers associated with cardiovascular disease (CVD) risk. By offering a simple, at-home-compatible test, the company aims to address the significant unmet need for early, accessible CVD risk assessment, potentially reducing the burden of the world's leading cause of death. As a private company with no disclosed funding or revenue, Alpspitz represents an early-stage venture in the digital diagnostics space, with its platform still in development and validation phases. The company's value proposition centers on the combination of non-invasive sampling, AI-driven biomarker analysis, and a focus on inflammation—a key driver of CVD. If successful, DefenceDX could disrupt traditional blood-based risk screening by improving patient compliance and enabling population-wide preventive care. However, the company faces challenges typical of early-stage diagnostics, including clinical validation, regulatory clearance (e.g., CE marking in Europe), and commercial scalability. Given the lack of public milestones, the technology's readiness and market traction remain unverified, placing Alpspitz in a high-risk, high-reward category within the broader diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026Completion of initial clinical validation study40% success
• Q2 2027Securing Series A funding35% success
• TBDStrategic partnership with a healthcare provider or diagnostics distributor30% success